Clinical trials: Resistant Major Depression
Resistant Major Depressive Disorder
DBS in Treatment Resistant Major Depression
This study aims at assessing efficacy and safety of DBS for treatment of patients suffering from resistant major depression, by means of a random, controlled and crossed study.
- Trial name
- NCT01268137
- Testing
- Deep Brain Stimulation
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Major Depressive Disorder, Recurrent, Unspecified
Deep Brain Stimulation of Nucleus Accumbens for Chronic and Resistant Major Depressive Disorder
Depression is a common, recurrent and disabling disorder. Among patients with a chronic course of the disease, 20 to 30% are resistant to antidepressant medications.
- Trial name
- PRESTHYM (NCT01569711)
- Testing
- Deep brain stimulation of nucleus accumbens
- Where
- 10 sites in France
- Volunteers
- 6 people
- Sponsor
- Rennes University Hospital
Treatment Resistant Depression, Depression - Major Depressive Disorder
Characterizing Synaptic Density in Treatment Resistant Depression
The purpose of this study is to better understand how certain brain systems work in people with depression, especially in those whose symptoms have not improved with antidepressant treatments.
- Trial name
- TPET (NCT03537794)
- Testing
- PET scans
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Major Depressive Disorder, Anhedonia
Psilocybin for Treatment-Resistant Depression
The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.
- Conditions
- Major Depressive Disorder, Anhedonia, Treatment Resistant Depression
- Trial name
- NCT06230757
- Testing
- Psilocybin 25mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)
The goal of this clinical trial is to learn if intravenous (IV) ketamine with Dialectical Behavioural Therapy (DBT) reduces suicidal ideation in individuals with suicidality who have been diagnosed with Borderline Personality…
- Conditions
- Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder, Treatment-resistant Bipolar Depression, Major Depressive Disorder (MDD)
- Trial name
- KET-DBT (NCT07569198)
- Testing
- Ketamine Hydrochloride, Midazolam Hydrochloride, Dialectical Behavioral Therapy (DBT)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Joshua Rosenblat
Major Depressive Disorder
Comparative Effectiveness Clinical Trial of MST Compared to ECT in Major Depressive Disorder
This study was a prospective, open-label comparative effectiveness clinical trial, comparing magnetic seizure therapy (MST) to ECT in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT04216095
- Testing
- Electroconvulsive Therapy (n=30), Magnetic Seizure Therapy (n=30)
- Volunteers
- 60 people
- Sponsor
- Tanta University
Depressive Disorder, Major
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI)…
- Trial name
- ESCAPE-LTE (NCT04829318)
- Testing
- Esketamine, SSRI/SNRI
- Where
- 59 sites in Argentina, Belgium and 12 more
- Volunteers
- 183 people
- Sponsor
- Janssen-Cilag Ltd.
Depressive Disorder, Treatment-Resistant
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy compared with placebo in patients with major depressive disorder (MDD) who have shown an inadequate…
- Trial name
- NCT02153502
- Testing
- AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
- Where
- 32 sites in United States
- Volunteers
- 206 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Treatment Resistant Depression
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic…
- Trial name
- TRANSCEND (NCT06423430)
- Testing
- Active-stimulation
- Where
- 26 sites in United States
- Volunteers
- 100 people
- Sponsor
- Abbott Medical Devices
Major Depressive Episode
The RAFT ECT Study
Severe depression is devastating for those affected and is often associated with significant risk of suicide. Electroconvulsive therapy (ECT) is a highly effective acute treatment for severe depression, but its use and…
- Trial name
- RAFT-ECT (NCT05402657)
- Testing
- Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
- Where
- 7 sites in United States, Australia
- Volunteers
- 156 people
- Sponsor
- The George Institute
Treatment-Resistant Major Depressive Disorder
Avatar Therapy in Virtual Reality for Treatment-Resistant Major Depressive Disorder: A Pilot Study
This pilot clinical trial aimed to evaluate the short-term efficacy of Avatar therapy for treatment-resistant major depressive disorder
- Trial name
- NCT07112261
- Testing
- Avatar Therapy
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Depressive Disorder, Major, Treatment Resistant Depression
Stepped Care AiTBS 2 Depression Study (Ghent)
Antidepressant-free unipolar melancholic depressed patients (at least stage 2 treatment-resistant) will be selected by a certified psychiatrist, who will administer (semi-)structured clinical interviews.
- Conditions
- Depressive Disorder, Major, Treatment Resistant Depression, Melancholia
- Trial name
- aiTBS2-Ghent (NCT03288675)
- Testing
- aiTBS, CCT, SSRI
- Where
- Belgium
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Depressive Disorder, Major
A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)
The purpose of this study is to determine whether the Cervel Neurotech rTMS device is safe and effective in the treatment of depression in people who do not get better with antidepressant medications or cannot take antidepressant…
- Trial name
- NCT01909232
- Testing
- Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator, Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
- Where
- 6 sites in United States
- Volunteers
- 92 people
- Sponsor
- Cervel Neurotech, Inc.
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Home-Based Randomized Trial of Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression
This study aims to evaluate the clinical efficacy and neurophysiological mechanisms of home-based spaced tDCS in TRD through a randomized, double-blind, sham-controlled trial conducted under remote supervision.
- Trial name
- NCT07834762
- Testing
- Spaced Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Diego
Multiple Sclerosis, Major Depressive Disorder
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS.
- Conditions
- Multiple Sclerosis, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT06329414
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Major Depressive Disorder, Depression
Is Brain Insulin Resistance a Feature of the Biology of Depression in Adolescents
This study will examine if brain insulin resistance is a feature of depression in humans using magnetic resonance imaging (MRI) measures sensitive to brain insulin action.
- Trial name
- NCT05571878
- Testing
- Humalog, Saline nasal spray
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder (MDD)
tVNS, Motivation, and Insulin Sensitivity
Disturbances in energy metabolism significantly increase the risk of developing major depressive disorder (MDD), especially in individuals with type 2 diabetes.
- Trial name
- NCT07198100
- Testing
- Transcutaneous non-invasive vagus nerve stimulation (tVNS), Oral glucose tolerance test (oGTT)
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Treatment Resistant Major Depressive Disorder
This is a Study to Determine the Antidepressant Effects of AZD6765
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
- Trial name
- NCT00986479
- Testing
- AZD6765
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Major Depressive Disorder, Bipolar Disorder
Brain Insulin Resistance in Mood Disorders
The overarching aim of the study is to determine the role of insulin signaling on the neurobiological substrates subserving anhedonia within individuals with mood disorders (i.e., Bipolar Disorder (BD) and Major Depressive…
- Conditions
- Major Depressive Disorder, Bipolar Disorder, Anhedonia, Intranasal Insulin
- Trial name
- NCT03915613
- Testing
- Humulin R, Diluent
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Depression
Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder
The purpose of the study is to test whether oral 6(S)-5-MTHF (Deplin) is safe and effective in relieving depression when it is added to standard kinds of antidepressants called serotonin reuptake inhibitors (SSRIs).
- Trial name
- TRD-2 (NCT00955955)
- Testing
- 6(S)-5-MTHF(Deplin)
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- George I. Papakostas